XLXiaodong Lv

Xiaodong Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaodong Lv has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comorbidity between respiratory system diseases and atherosclerosis: mechanisms and potential treatments

    by Jie Qin, Lijian Pang, Ningzi Zang, Jiaran Wang, Jiyu Zou, Ziyi Liu, Xiaodong Lv

  • Open Access

    Exploring the Mechanisms of Total Saponins of Black Ginseng and Ginsenoside Rg3 Against Doxorubicin‐Induced Cardiotoxicity

    by Linlin Liu, Peiyuan Dou, Xiaotong Zhang, Xiaoku Ran, Deqiang Dou, Xiaodong Lv

    Doxorubicin (DOX), a widely utilized chemotherapeutic agent, is constrained by its intricate cardiotoxicity, which involves oxidative stress, mitochondrial dysfunction, and cell death. Black ginseng (BG), processed to enhance rare saponins such as ginsenoside Rg3, demonstrates augmented anticancer and cardioprotective properties. The combination of DOX with total saponins of BG (TSF) or the active component Rg3 may provide synergistic antitumor effects while mitigating cardiotoxicity, although the underlying mechanisms necessitate further investigation. This study aimed to evaluate the protective effects of TSF and Rg3 against DOX‐induced cardiotoxicity (DIC) and to explore their potential to enhance mitochondrial function by modulating the HDAC8/BRCA2/DRP1 pathway. The research involved in vitro studies using H9c2 cells and in vivo experiments with mouse models to assess the pharmacological actions of TSF and Rg3. Network pharmacology was employed to predict the potential mechanisms by which TSF regulates the HDAC8/BRCA2/DRP1 pathway. Verification was conducted through Western blot analysis and immunofluorescence colocalization techniques. In vitro experiments demonstrated that TSF and Rg3 enhanced the viability of H9C2 cells subjected to DOX induction. In vivo studies revealed that TSF and Rg3 significantly improved cardiac function and mitigated myocardial structural damage in mice. Notably, the effects of Rg3 were particularly pronounced. TSF and Rg3 also effectively reduced oxidative stress markers, such as SOD and MDA, and decreased inflammation. Furthermore, they inhibited apoptosis, restored cardiomyocyte morphology, and enhanced mitochondrial function by increasing ATP activity. Cyberpharmacological analysis suggested that the HDAC8/BRCA2/DRP1 signaling pathway may be a target for regulation by TSF and Rg3 during DOX‐induced progression. Our findings demonstrated that TSF and Rg3 reverse DOX‐induced upregulation of HDAC8 and DRP1 protein expression while downregulating BRCA2 protein expression in cardiac tissues. Additionally, immunofluorescence colocalization confirmed direct interactions among HDAC8, BRCA2, and DRP1. TSF and Rg3 demonstrate significant cardioprotective effects against DIC by mitigating oxidative stress, inflammation, and apoptosis, while preserving mitochondrial function. These findings provide novel insights into the clinical relevance of TSF and Rg3 in the management of DIC. The regulation of the HDAC8/BRCA2/DRP1 pathway underscores the potential of TSF and Rg3 as a promising therapeutic strategy for the prevention and treatment of DIC.

  • Open Access

    Correction: Explanation of the potential mechanism of Sophora flavescens Ait and processed products treating ulcerative colitis based on the analysis method of “chemical composition characterization-target prediction”

    by Xiaoting Wang, Yue Liu, Tianni Jiang, Xiaodong Lv, Hui Gao

    Correction for ‘Explanation of the potential mechanism of Sophora flavescens Ait and processed products treating ulcerative colitis based on the analysis method of “chemical composition characterization-target prediction”’ by Xiaoting Wang et al. , RSC Adv. , 2025, 15 , 11354–11369, https://doi.org/10.1039/D4RA04760E.

  • Open Access

    Effectiveness and safety of four drainage methods for lung abscess: a Bayesian network meta-analysis and systematic review

    by Xuxin Zhang, Yin Zheng, Lijian Pang, Xiaodong Lv, Ningzi Zang

    Objective: To compare the efficacy and safety of various pus drainage methods for lung abscess via network meta-analysis. Methods: Randomized controlled trials (RCTs) from PubMed, Embase, Scopus, Web of Science, VIP, Wanfang, and CNKI were searched up to April 2025. Study quality was assessed using the Cochrane Risk of Bias Tool (v5.4.0). Bayesian network meta-analysis was conducted using Rstudio (v4.4.1). Results: A total of 23 RCTs (1,453 patients) evaluating four drainage techniques were included. Effective rate: CT-guided percutaneous drainage + antibiotics ranked highest (77% probability), outperforming antibiotics alone (OR = 5.4) and conventional postural drainage + antibiotics (OR = 7.4). Hospital stay: Ultrasound-guided drainage + antibiotics ranked best (89% probability), significantly reducing stay versus conventional postural drainage + antibiotics (MD = –19 days). Symptom resolution: Ultrasound-guided drainage + antibiotics ranked highest for cough (SUCRA 97%) and fever resolution (SUCRA 97%). Lesion reduction: Modified postural drainage + antibiotics ranked highest (98% probability), surpassing conventional postural drainage + antibiotics (OR = 0.48) and antibiotics alone (OR = 0.15). Conclusion: Comprehensive analysis indicates that ultrasound-guided percutaneous drainage combined with antibiotics demonstrates the highest probability of improvement in key outcome measures, including time to fever resolution, length of hospital stay, and time to cough resolution, potentially showcasing a comprehensive potential for clinical benefit. CT-guided percutaneous drainage combined with conventional antibiotic therapy may be the most effective in terms of the effective rate, while modified postural drainage combined with conventional antibiotic therapy may be the most prominent in increasing the number of lesion reduction. Furthermore, conventional antibiotic therapy alone was inferior to pus drainage procedures combined with conventional antibiotics across multiple outcome measures and was associated with a higher incidence of adverse reactions. However, due to the limited number of available studies, these findings can only be considered preliminary. Future validation through a substantial number of multicenter, large-sample, double-blind randomized controlled trials is warranted. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251127786.


  • Open Access

    Evidence map analysis of clinical studies on 42 commonly used oral Chinese patent medicines for the treatment of stable chronic obstructive pulmonary disease

    by Jingze Li, Quan Yuan, Ruizhi Yu, Lijian Pang, Tianjiao Wang, Ningzi Zang, Linlin Wang, Zhongxue Zhao, Lingyun Zhu, Can Yang, et al.


  • The mechanism of Shenlong Jianji treatment of idiopathic pulmonary fibrosis inhibits fibroblast-to-myofibroblast transformation via the TGF-β1/smads signaling pathway

    by Jiaxiang Pan, Yue Li, Xize Wu, Xue Pan, Chuang Liu, Haoyang Zhang, Linlin Wang, Xin Jiang, Jiaran Wang, Ningzi Zang, et al.


  • A Bibliometric Analysis and Scientific Knowledge Map Study of the Current Status and Development Trend of Pulmonary Rehabilitation

    by Ningzi Zang, Jiyu Zou, Shiwen Wang, Pin Li, Yongming Liu, Jiaran Wang, Lijian Pang, Xiaodong Lv

    Background: The field of pulmonary rehabilitation (PR) is gaining attention and research in clinical application year by year. This study aims to analyze the current status, hot topics, research frontiers and future trends of research in the field of pulmonary rehabilitation. Methods: Based on the Web of Science Core Collection (WoSCC) database, articles on pulmonary rehabilitation published between January 1st, 2010, and July 1st, 2023, were retrieved. Only articles published in English were included. Collaborative network analysis of the annual number of publications, countries/regions, institutions, journals, keywords, authors, and co-citation analysis of references were conducted using CiteSpace 6.2.R2 Advanced and VOSviewer1.6.18 software. Results: A total of 5408 articles related to pulmonary rehabilitation were included in the study, with 703 keywords. The United States is the leading country with the most annual publications, and Maastricht University is the most active institution. The International Journal of Chronic Obstructive Pulmonary Disease is the most published, while the American Journal of Respiratory and Critical Care Medicine is the most cited. Spruit Martijn A, Franssen, and Frits ME are the most published researchers in this field. The keywords co-occurrence analysis showed that the current research hotspots and frontiers are: ① fully revealing the clinical effect and potential of pulmonary rehabilitation, and deeply exploring its influence on related indicators and comorbidities of various chronic respiratory diseases, ② continuing to improve the pulmonary rehabilitation treatment strategy, chronic obstructive pulmonary disease (COPD), exercise training, and lung cancer status before and after surgery are still the main research directions, ③ due to the Corona Virus Disease 2019 (COVID-19) pandemic, not only pulmonary rehabilitation in hospitals, but also home pulmonary rehabilitation has attracted wide attention. Conclusions: At present, pulmonary rehabilitation strategies, various chronic respiratory diseases, exercise methods and quality of life assessment are still hot research topics in this field. In the future, it is suggested to gradually improve the pulmonary rehabilitation strategy, improve the applicability and accessibility of the pulmonary rehabilitation program, and continue to pay attention to the long-term outcome of pulmonary rehabilitation.

  • A Bibliometric Analysis and Scientific Knowledge Map Study of the Current Status and Development Trends of Drug Therapy Related to Pulmonary Fibrosis

    by Ningzi Zang, Shiwen Wang, Jiyu Zou, Pin Li, Yongming Liu, Lijian Pang, Xiaodong Lv

    Objective: Recently, the study of pulmonary fibrosis drugs has been increasing steadily. The value of the clinical application of these drugs has been widely concerned. This study aimed to analyze the current status, hot contents, research frontiers and developing trends surrounding drugs for treating patients with pulmonary fibrosis. Methods: Articles concerning drug therapy for pulmonary fibrosis published between 1 January 1980 and 5 October 2022 were retrieved from the Web of Science Core Collection (WOSCC) database. Only articles published in English were included. Collaborative network analysis of annual publications, countries/regions, institutions, journals, keywords, authors and co-citation analysis of references were shown by CiteSpace 6.1.R2 and VOSviewer 1.6.18 software. Results: 502 articles and 522 keywords on pulmonary fibrosis drugs were included. China was the leading country with the most annual publications and Beijing Univ Chinese Med was the most active institution. The most published journal was Frontiers in Pharmacology and the most cited journal was American Journal of Respiratory and Critical Care Medicine. Maghu Toby TM and Bouros Demosthenes were the most published researchers in this field. 958 articles were cited from 1980 to 2022, mainly derived from influential journals such as The New England Journal of Medicine (Q1, impact factor 176.079). The co-occurrence of keywords showed that the current research hotspots and frontiers were as follows: ① Fully revealing the role and potential of existing drugs, determining the best route of administration, and proposing ideas for drug combinations; ② Conducting further research on the diagnosis, efficacy, survival and evaluation of idiopathic pulmonary fibrosis, cancer, and lung injury; ③Based on star signal transduction pathways and molecules, studying the intervention mechanisms of pulmonary fibrosis surrounding various pathological phenotypes such as the inflammatory response and dysregulation of oxidative stress; ④ Gaining a better understanding of the mechanisms of action of pirfenidone and nintedanib. Conclusions: This study reveals the global research hotspots and developing trends of drugs for pulmonary fibrosis patients, and helps researchers quickly understand the current research status and hot contents in this growing field.

  • Open Access

    Transcriptome Sequencing of lncRNAs, circRNAs, miRNAs, mRNAs, and Interaction Network Constructing in Acute Exacerbation of Idiopathic Pulmonary Fibrosis

    by Ningzi Zang, Jiaran Wang, Jingyu Wang, Tingting Li, Pin Li, Yongming Liu, Jiaxiang Pan, Lijian Pang, Xiaodong Lv

    Background: Idiopathic pulmonary fibrosis (IPF) patients who suffer from acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) are at increased risk of respiratory deterioration and death. Non-coding RNAs (ncRNAs) play a vital role in AE-IPF, but studies of crosstalk between transcripts of IPF based on Traditional Chinese Medicine (TCM) syndrome type are relatively few. The construction of long non-coding RNAs (lncRNA)/circular RNAs (circRNA)-microRNAs (miRNA)-mRNA interaction networks can promote understanding RNA interaction in different syndrome types of AE-IPF. The study aimed to identify the difference in RNA transcription expression between IPF patients with “lung heat and collateral stasis (LHCS)” and “lung deficiency with collateral stasis (LDCS)” syndromes, further to construct the potential RNA networks. Methods: Five IPF patients with LHCS and five IPF patients with LDCS were recruited in this study to perform RNA sequencing and miRNA sequencing. Further analysis was carried out on the differential expression profiles of lncRNAs, circRNAs, miRNAs, and mRNAs among patients with LHCS and LDCS. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. The lncRNA/circRNA-miRNA-mRNA competing endogenous RNAs (ceRNAs) network was constructed, and the key regulatory molecules were analyzed. Results: For LHCS and LDCS, we identified 69 lncRNAs, 150 circRNAs, 27 miRNAs, and 56 mRNAs. Differential expression analysis through GO and KEGG highlights that differentially expressed mRNAs have significant associations with pathways such as tight junction and Hepatitis C. Within the ceRNA network, all nodes have a direct or indirect association with LHCS progression. The hsa-miR-150-5p core sub-network is composed of 1 lncRNA, 6 circRNAs, 1 miRNA, and 5 mRNAs. From the ceRNA sub-network analysis, NR_120628/hsa-miR-150-5p/E2F3 and hsa-circ-0053515/hsa-miR-150-5p/E2F3 emerged as the pivotal ceRNA pairs. Conclusions: This study highlights that the NR_120628/hsa-miR-150-5p/E2F3 and hsa-circ-0053515/hsa-miR-150-5p/E2F3 axes could be central in the regulation of LHCS, providing valuable insights into potential directions for subsequent research on LHCS. Trial registration: Chinese clinical trial registry (CHiCTR23007405). Registered on July 27, 2023. https://www.chictr.org.cn/.